Wall Street brokerages expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to announce ($0.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.49). Spring Bank Pharmaceuticals reported earnings per share of ($0.47) during the same quarter last year, which suggests a negative year over year growth rate of 6.4%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 19th.
On average, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($1.76) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.53). For the next year, analysts anticipate that the company will post earnings of ($2.26) per share, with EPS estimates ranging from ($2.67) to ($1.90). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings data on Thursday, October 25th. The company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.01.
In related news, insider Martin J. Driscoll acquired 4,000 shares of the stock in a transaction that occurred on Monday, August 13th. The stock was purchased at an average cost of $12.02 per share, for a total transaction of $48,080.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 15.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. Jennison Associates LLC acquired a new position in Spring Bank Pharmaceuticals during the 3rd quarter worth $8,210,000. BlackRock Inc. boosted its position in Spring Bank Pharmaceuticals by 25.0% during the 3rd quarter. BlackRock Inc. now owns 604,067 shares of the company’s stock worth $7,279,000 after acquiring an additional 120,809 shares during the period. Morse Asset Management Inc boosted its position in Spring Bank Pharmaceuticals by 7.1% during the 3rd quarter. Morse Asset Management Inc now owns 190,050 shares of the company’s stock worth $2,290,000 after acquiring an additional 12,550 shares during the period. Millennium Management LLC boosted its position in Spring Bank Pharmaceuticals by 82.3% during the 1st quarter. Millennium Management LLC now owns 91,663 shares of the company’s stock worth $1,410,000 after acquiring an additional 41,372 shares during the period. Finally, C WorldWide Group Holding A S boosted its position in Spring Bank Pharmaceuticals by 4.9% during the 2nd quarter. C WorldWide Group Holding A S now owns 91,567 shares of the company’s stock worth $1,085,000 after acquiring an additional 4,245 shares during the period. Institutional investors own 27.11% of the company’s stock.
SBPH traded down $0.60 during trading on Friday, reaching $11.18. 70,094 shares of the company were exchanged, compared to its average volume of 58,679. The company has a market cap of $194.08 million, a P/E ratio of -5.98 and a beta of 0.89. Spring Bank Pharmaceuticals has a 52 week low of $8.88 and a 52 week high of $18.93.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.